Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
5Y6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.60 - €9.00
Previous CloseN/A
Volume0.00
Average Volume (3M)93.00
Market Cap
$181.19M
Enterprise Value€256.10M
Total Cash (Recent Filing)$165.08M
Total Debt (Recent Filing)$32.19M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 08, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding92,673,134
10 Day Avg. Volume11
30 Day Avg. Volume93
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
€16.39Price Target Upside525.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends buying Compass Pathways plc stock, reflecting confidence in its future potential.
Financial HealthCMPS finished with $165.1M in cash and cash equivalents, indicating strong financial health.
Market PotentialCOMP360’s differentiated profile—demonstrated rapid efficacy, potential durability, and scalability versus SPRAVATO (esketamine)—positions it as a transformative treatment in treatment-resistant depression (TRD).
Bears Say
Stock DilutionThe stock price target has been adjusted from $23 to $15 primarily due to dilution from a recent offering.
Stock Upside LimitationOutstanding warrants exercisable on the release of the 26-week data from the COMP005 study have the potential to limit the stock's upside.
Trial ConcernsThe decision was influenced by the negative Lykos AdComm and CRL, raising concerns about trial design and management.
---
Options Prices
Currently, No data available
---
Ownership Overview
22.00% Insiders
0.22%
Mutual Funds
22.97% Other Institutional Investors
51.88% Public Companies and
Individual Investors
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €2.60 and its highest was €9.00 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $181.19M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 08, 2025 which is in 36 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Feb 27, 2025. The company reported -€0.582 earnings per share for the quarter, missing the consensus estimate of -€0.579 by -€0.004.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.45.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 92,673,134 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.582 in its last earnings report, missing expectations of -€0.579. Following the earnings report the stock price went up 10.119%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in DE:5Y6
---
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€16.39 (525.39% Upside)
€16.39 (525.39% Upside)
Blogger Sentiment
Bullish
DE:5Y6 Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.62%
12-Months-Change
Fundamentals
Return on Equity
-81.56%
Trailing 12-Months
Asset Growth
-22.58%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
---
5Y6 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights COMPASS Pathways' solid financial position and progress in clinical trials, particularly for TRD and PTSD, with strategic collaborations enhancing market insights. However, increased net loss and operational costs present financial challenges.Read More>---
5Y6 Stock 12 Month Forecast
Average Price Target
€16.39
▲(525.39% Upside)
Technical Analysis
Best Analysts Covering 5Y6
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-35.87%
reiterated a buy rating 2 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -35.87% per trade.
---